Rituximab-induced hypersensitivity pneumonitis.

Area of Science:

• Pulmonology
• Oncology
• Immunology

Background:

• Rituximab, a chimeric anti-CD20 monoclonal antibody, is a standard treatment for CD20+ non-Hodgkin's lymphoma.
• While common pulmonary side effects include cough and dyspnea, rare respiratory conditions have been reported.
• Hypersensitivity pneumonitis is an exceptionally rare adverse reaction to rituximab therapy.

Observation:

• A patient undergoing rituximab treatment developed symptoms consistent with hypersensitivity pneumonitis.
• Radiographic and histopathologic findings were classic for hypersensitivity pneumonitis.
• The patient's condition was diagnosed as rituximab-associated hypersensitivity pneumonitis.

Findings:

• The presented case details a rare instance of hypersensitivity pneumonitis linked to rituximab.
• The diagnosis was supported by characteristic imaging and biopsy results.
• This adds to the limited documented cases of this specific adverse reaction.

Implications:

• This case highlights the importance of considering hypersensitivity pneumonitis in patients on rituximab presenting with respiratory symptoms.
• Prompt recognition and treatment with corticosteroids, such as prednisone, may lead to favorable outcomes.
• Further investigation into the mechanisms and incidence of rituximab-induced hypersensitivity pneumonitis is warranted.